Dishman Pharma has been progressively declining and is sitting on a low after the company's bottomline guidance declined on account of mark-to-market (MTM) losses.
JR Vyas, Managing Director expects Dishman's key clients Abbott's contribution to grow by 50%. He further expects some more product orders coming in from Abbott in FY13. However, he also said that Abbott
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
